Chile Four Risk Classes: I, II, III and IV

1. Key takeaways

Article 20 of DS 825/1998 divides devices into Class I (extremely low risk), Class II (moderate risk), Class III (potentially high risk) and Class IV (most critical risk). The key structural feature is that the regulation provides only the four class definitions without attaching a classification catalog; the class of a specific product is designated by the category-by-category inclusion decree (Article 22).

GRZAN emphasizes one high-frequency error: Chilean classes cannot be copied from the EU or FDA. Cases in which the same product is Class IIa in Europe but Class III in Chile are not rare. Once a classification is judged wrongly, the entire dossier system must be redone — this is the most frequent and most expensive source of rework in Chilean projects, and it is entirely avoidable with a Chile-specific classification exercise at the start.

The reason the mismatch happens is structural. Chile does not ask applicants to classify their own products against a fixed catalog; it asks them to wait for the class named in the inclusion decree (Article 22), and until that designation exists, to reason from the class definitions of Article 20. Because the Chilean definitions were drafted in 1998 against a different reference framework than the EU rules or the FDA device categories, the boundary lines fall in different places. The practical consequence is that the classification conclusion must be produced fresh against the Chilean texts, with the European or American result treated only as an unverified prior expectation.

2. Legal basis

• Regulation on the control of medical products and devices | Decreto Supremo N° 825, de 1998 | August 21, 1999 | Article 20: devices are classified by risk into Classes I, II, III and IV, with definitions for each class.
• Same source | Article 21: the dossier requirements corresponding to each class (Class I: six items; Class II: additionally evidence of a quality system; Class III: additionally scientific literature, studies on effectiveness and safety, and evidence of a quality system; Class IV: additionally studies in representative patient populations, studies of inherent risks and biological studies).
• Same source | Article 22: the category of each specific device is designated by the inclusion decree.
• Decree including listed devices in the sanitary control regime of Article 111 | Decreto Exento N° 25, de 2026 | March 19, 2026 | the list annotates the class of each product (including Class II, III and IV devices and Class B, C and D IVDs).

3. Expert insights

Insight 1: classification works through five questions, not through the assumption that implantable means the highest class.

Classification depends on: intended use, invasiveness, duration of contact with the body, contact with the central circulatory or nervous system, and whether energy or medicinal substances are delivered. Implantability is only one of these elements. The list of the Decreto Exento N° 25, de 2026 confirms the point: cardiovascular catheters and stents are placed in Class IV (the highest band, with the 24 months transition period), whereas most non-implantable interventional devices (peripheral diagnostic catheters, guidewires, introducer sheaths) fall in Class II or III and carry the 36 months transition period. Reasoning from implantability alone produces wrong answers in both directions.

Insight 2: the class directly binds the dossier ladder and the transition period, producing a chain reaction.

Class → Article 21 dossier requirements → budget and timeline → transition-period band (implantable and higher-risk products at 24 months, everything else at 36 months) → production planning priority. A single difference in class determination can simultaneously change the budget, the timeline and the market window, which is why classification errors are so costly relative to the effort of getting them right.

Insight 3: because the inclusion decree designates the class, an official classification opinion is safer than self-judgment.

Article 22 vests the designation of specific classes in the inclusion decree; for products not yet included, companies may self-assess with reference to the ISP classification guidance (2018 version) and may raise classification consultations through official channels. GRZAN recommends written consultation for borderline products, moving the judgment risk forward to a stage where it costs a letter rather than a rejected dossier.

The chain reaction also runs in reverse, which is why the class determination deserves its own quality gate. Before the dossier matrix is built, the class feeds the Article 21 requirements; before the budget is approved, the requirements feed cost and duration; before production planning is frozen, the transition-period band feeds the market-entry window. Any of these downstream artifacts can be produced twice, but only at multiplied cost. Fixing the class once, in writing, with the five elements documented, is the cheapest point in the entire project to absorb uncertainty.

4. Practical recommendations

1. Use the five-question method for the classification determination document: intended use, invasiveness, duration of contact, contact with the central circulatory or nervous system, and delivery of energy or medicinal substances, recording the conclusion and the basis for each item.
2. Request an ISP classification consultation for borderline products, attaching the written reply to the submission to reduce the probability of deficiency letters.
3. Rebuild the dossier matrix around the Chilean class, rather than carrying over the technical file structure used for the EU or FDA.
4. Feed class and transition period into production planning: Class IV and implantable products start first; Class II and III products are scheduled according to the publication of the applicable guidance.

5. Verification checklist

• □ Issued the four-class determination under Article 20 with written records
• □ Recorded the classification elements item by item using the five-question method
• □ Confirmed the class annotation of the product in the list of the Decreto Exento N° 25, de 2026
• □ Rebuilt the Article 21 dossier matrix around the Chilean class
• □ Determined the transition-period band (24 or 36 months) and the production planning priority according to class

Regulatory information verified as of October 29, 2026.

For a Chile market-entry feasibility assessment covering your specific product, contact the GRZAN regulatory team. GRZAN provides ISP registration and compliance support for the Chilean market: five-question classification determinations, ISP consultation handling, Chile-specific dossier matrices, and transition-period production planning. Reach us at info@grzanglobal.com.